Answers are grounded in this paper and cite their sources.
Investigates the role of Caspase14 in promoting drug resistance in MCF-7 breast cancer cells, suggesting a therapeutic target for tamoxifen resistance.
Breast cancer therapy is compromised by widespread tamoxifen resistance. The modulatory role of Caspase14 in the early growth response protein 1 (EGR1)/hypoxia-inducible factor 1-alpha (HIF-1α) axis in this context is unclear. We investigated how Caspase14 regulates EGR1/HIF-1α to promote 4-hydroxytamoxifen (4-OHT) resistance in MCF7 cells using cell-based genetic and biochemical assays (small-interference RNA knockdown, plasmid overexpression, Western blotting, qPCR, IC50 assays, and Chromatin immunoprecipitation experiments) across multiple independent experiments. Caspase14 expression correlated with resistance, with IC 50 rising from 0.178 µM to 1.575 µM in resistant variants. EGR1 knockdown reduced Caspase14 and downstream targets GLUT3 and BCRP, implicating EGR1 as a key mediator. Resistant cells displayed elevated HIF-1α that enhanced metabolism and migration, further supporting a role in drug resistance. These data indicate that Caspase14 promotes survival, proliferation, and metabolic reprogramming in resistant MCF7 cells via the EGR1/HIF-1α pathway. Our findings reveal a mechanistic link between Caspase14 and endocrine therapy resistance and nominate Caspase14 as a therapeutic target to overcome tamoxifen resistance, with potential translational relevance.
No takes yet. Share an insight, caveat, or question.
季飞虎 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: